树突细胞单抗对同种带瓣主动脉移植影响

Experimental studies on the use of dendritic cell monoclonal antibody in aortic valve homografting

目的探讨树突细胞单抗(DCmAb)对同种带瓣主动脉(AVH)免疫原性的影响及在改善AVH移植远期疗效中的作用。方法选成年Wistar大鼠(200～250g)为供体,SD大鼠(200～250g)为受体,采用大鼠AVH腹主动脉移植模型。实验分3组。A组(n=12)供体接受1∶10稀释DCmAb处理;B组(n=12)供体接受1∶20稀释DCmAb处理;C组(n=12)为对照,接受新鲜AVH移植。术后2、4、8、12周测定血ICAM1、TCRαβ的表达,移植标本组织病理学观察。结果A组术后2～4周ICAM1分别为(7.603±1.665)%和(13.963±0.376)%,明显低于C组的(9.023±2.582)%和(17.060±2.6465)%(P<0.05,P<0.01);术后两周,A、B两组TCRαβ分别为(30.91±2.099)%和(34.893±2.303)%,与C组相比均明显降低(P<0.01),A组降低幅度大于B组(P<0.05)。病理观察显示:C组变化成典型排斥反应改变。A组各时期病理损害明显较C组减轻,出现时间延迟,B组处于A、C而组之间。结论DCmAb可减少AVH的免疫原性,减轻移植术后病理损害。其作用呈一定的量效关系。

To evaluate the effect of dendritic cell monoclonal antibody (DcmAb) on the immunogenicity of aortic valve homograft(AVH),and the role in improvement of AVH durability. Methods Rat AVHs were heterotopically allografted onto abdominal aorta from Wistar to SD rats The animals were divided into 3 groups.Group A (n=12)received AVHs treated with DcmAb diluted by 1∶10.Group B(n=12)received AVHs treated with DcmAb diluted by 1∶20.Group C(n=12)receivd nontreated AVHs as controls. Results The expression of ICAM-1,TCR-αβ were tested and histological studies of the explants were taken at 2?4?8?12 weeks postimplantively. The expressions of ICAM-1 in group A at 2 and 4 weeks were(7.603±1.66)% and (13.963±0.376)%,singnificantly less than that in group C[(9.023±2.582)% and (17.060±2.6465)%,P<0.05 and P<0.01].The expressions of TCR-αβ in group A and B in 2 weeks were (30.91±2.099)% and (34.893±2.303)%,markedly less than that in group C(all with P<0.01).The expression of TCR-αβ in 2 weeks in group A was lower than that in group B (P<0.05).Histological study showed a marked mitigation of rejection response in group A,but lighter than that in group C.Treatment with DcmAb casused a decrease of immunogenicity efficacy,and mitigation in pathological damage after implantation. Conclusion The efficiency of DcmAb relates to it's concentration.